Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
$2.20
-2.7%
$3.31
$2.12
$42.00
$7.74M0.45157,752 shs49,449 shs
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
$5.68
-12.1%
$4.91
$2.96
$9.85
$9.69M-0.0539,983 shs24,525 shs
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
$11.05
-2.3%
$10.84
$8.67
$35.70
$7.85M1.0620,583 shs2,433 shs
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$2.56
+0.4%
$3.17
$2.50
$21.75
$2.03M1.37977,168 shs40,118 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
-0.88%-1.31%-18.71%-56.70%-93.02%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
+22.58%+18.75%+55.29%+35.43%+50.93%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
+2.69%-1.47%+6.01%+5.13%-60.18%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-1.92%-7.94%-13.27%-48.51%-82.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
$2.20
-2.7%
$3.31
$2.12
$42.00
$7.74M0.45157,752 shs49,449 shs
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
$5.68
-12.1%
$4.91
$2.96
$9.85
$9.69M-0.0539,983 shs24,525 shs
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
$11.05
-2.3%
$10.84
$8.67
$35.70
$7.85M1.0620,583 shs2,433 shs
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$2.56
+0.4%
$3.17
$2.50
$21.75
$2.03M1.37977,168 shs40,118 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
-0.88%-1.31%-18.71%-56.70%-93.02%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
+22.58%+18.75%+55.29%+35.43%+50.93%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
+2.69%-1.47%+6.01%+5.13%-60.18%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-1.92%-7.94%-13.27%-48.51%-82.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
2.20
Hold$52.502,286.36% Upside
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
2.00
Hold$25.00340.14% Upside
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
2.33
HoldN/AN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
2.00
Hold$25.00876.56% Upside

Current Analyst Ratings Breakdown

Latest VRAX, NDRA, ICCM, and NVNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
DowngradeHoldStrong Sell
8/13/2026
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
DowngradeSell (D-)Sell (E+)
7/31/2026
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
UpgradeSell (E+)Sell (D-)
7/17/2026
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
Reiterated RatingSell (E+)
7/17/2026
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
Reiterated RatingSell (E+)
7/7/2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
UpgradeHold
7/6/2026
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
Reiterated RatingSell (E+)
7/6/2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
UpgradeHoldStrong-Buy
6/30/2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
DowngradeSell (D-)Sell (E+)
6/15/2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
UpgradeSell (E+)Sell (D-)
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
$3.38M2.23N/AN/A$3.47 per share0.63
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/A$4.21 per shareN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/A$29.75 per shareN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
$10K204.80N/AN/A$42.23 per share0.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
-$15.06M-$8.52N/AN/AN/A-427.67%-174.26%-112.58%11/18/2026 (Estimated)
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-$7.03M-$6.38N/AN/AN/AN/A-246.34%-150.81%11/13/2026 (Estimated)
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$19.47M-$19.33N/AN/AN/AN/A-62.28%-56.83%10/30/2026 (Estimated)
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-$5.02MN/AN/AN/AN/AN/AN/AN/AN/A

Latest VRAX, NDRA, ICCM, and NVNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
-$0.84-$0.63+$0.21$0.06$0.10 millionN/A
7/30/2026Q2 2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$4.69-$5.37-$0.68-$5.37$1.00 millionN/A
7/3/2026Q4 2026
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
-$1.75-$0.1950+$1.5550-$0.1950$0.00 million$0.01 million
6/30/2026Q2 2026
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
N/A-$1.60N/A-$1.5970N/A$0.91 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
N/AN/AN/AN/AN/A
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/AN/AN/AN/AN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/AN/A
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
N/A
2.88
2.44
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
N/A
7.10
7.10
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A
11.70
11.70
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
N/A
9.97
9.97

Institutional Ownership

CompanyInstitutional Ownership
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
0.62%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
1.19%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
34.71%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
8.61%

Insider Ownership

CompanyInsider Ownership
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
2.44%
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
10.00%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
15.00%
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
45.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
IceCure Medical Ltd. stock logo
ICCM
IceCure Medical
603.43 million3.34 millionNot Optionable
ENDRA Life Sciences Inc. stock logo
NDRA
ENDRA Life Sciences
201.50 million1.35 millionNot Optionable
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
30690,000591,000No Data
Virax Biolabs Group Limited stock logo
VRAX
Virax Biolabs Group
5800,000438,000Not Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IceCure Medical stock logo

IceCure Medical NASDAQ:ICCM

$2.20 -0.06 (-2.65%)
As of 04:00 PM Eastern

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

ENDRA Life Sciences stock logo

ENDRA Life Sciences NASDAQ:NDRA

$5.68 -0.78 (-12.07%)
As of 04:00 PM Eastern

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

enVVeno Medical stock logo

enVVeno Medical NASDAQ:NVNO

$11.04 -0.26 (-2.26%)
As of 02:03 PM Eastern
This is a fair market value price provided by Massive. Learn more.

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

Virax Biolabs Group stock logo

Virax Biolabs Group NASDAQ:VRAX

$2.56 +0.01 (+0.39%)
As of 04:00 PM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.